Claritas Pharmaceuticals Inc V.CLAS.H

Today's news release

[MinimumDamage]

“We are delighted to add Dr. Cuzzocrea to the Company’s Board of Directors,” stated Robert Farrell, President and CEO. We are eager to begin work with Dr. Cuzzocrea on development of R-107.

Can anyone provide evidence if this is a retroactive news disclosure from the past 7 months halt or if this is happening as of right now? We are getting daily fresh info everyday since we unhalted and I suspect that we may be receiving everything that has happened during the cease trade order.

[AngelaL]

If you read the press release, carefully, you will note that it says that Cuzzocrea has carried out 40 studies on R-107. I will quote it for you here: Dr. Cuzzocrea brings expert knowledge of R-107 to Claritas, having carried out more than 40 studies of this molecule in the treatment of experimental models of acute lung injury, pulmonary arterial hypertension, wound healing, ischemia

[GajjarDr]

Yes, exactly what I was reflecting upon Miss.

[Dude51]

Hit the road loser. Still looking for that link, shiit for brains.

[MinimumDamage]

Dude51 - (3/5/2021 11:05:44 AM) RE:Today's news release Hit the road loser. Still looking for that link, shiit for brains. Kalytera Will Not Proceed with Acquisition of Salzman Group at This Time Following termination of the BARDA Contract, on about September 28, 2020 Kalytera determined that it was no longer in the best interests of the Company to go forward with the acquisition of the

[Cool_Law]

Here is the link for those that have interest in the stock....they will collaborate with the Salzman Group. Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections | 2021-03-03 | Press Releases | Stockhouse

[Dude51]

Your basing your BS on a 4 year old document. Get a life